GCA: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: GCA

NCBI ID: G25801

Content of Review Report on GCA Target / Biomarker

GCA

GCA: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

GCA (Grancalcin (isoform b)) is a drug target (or biomarker) that has been shown to have a potential for treating a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is a small molecule inhibitor of the enzyme calcineurin, which is involved in a variety of cellular processes, including cell signaling, DNA replication, and cell death.

GCA works by inhibiting the activity of calcineurin, which is an enzyme that is involved in many different cellular processes in the body. This inhibition can lead to the inhibition of the cell's ability to divide, grow, and communicate with other cells. This can result in the cell entering a state of dormancy or even death.

One of the ways that GCA is being studied as a potential drug target is its ability to treat various types of cancer. For example, studies have shown that GCA can inhibit the growth of cancer cells in both human and animal models. This makes it a potential treatment for a variety of cancers, including breast, lung, and ovarian cancers.

In addition to its potential use as a cancer treatment, GCA is also being studied for its potential use as a neurodegenerative disease treatment. Studies have shown that GCA can improve the survival rates and reduce the symptoms of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

GCA is also being investigated as a potential treatment for autoimmune disorders. Studies have shown that GCA can inhibit the activity of T cells, which are a type of immune cell that play a key role in many autoimmune disorders. This makes it a potential treatment for autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis.

GCA is a small molecule inhibitor of calcineurin, which is an enzyme that is involved in many different cellular processes in the body. This inhibition can lead to the inhibition of the cell's ability to divide, grow, and communicate with other cells. This can result in the cell entering a state of dormancy or even death. GCA is being studied as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its ability to inhibit the activity of calcineurin makes it a promising target for the development of new treatments for these diseases.

Protein Name: Grancalcin

Functions: Calcium-binding protein that may play a role in the adhesion of neutrophils to fibronectin. May play a role in the formation of focal adhesions

The "GCA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GCA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets